MAZE Stock Analysis: Buy, Sell, or Hold?
MAZE - Maze Therapeutics, Inc. Common Stock
$24.50
-1.06 (-4.15%)
▼
5d:
-4.0%
30d:
-12.78%
90d:
-47.84%
BUY
HIGH Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When MAZE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MAZE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MAZE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MAZE is currently trading at $24.50, which is considered oversold relative to its 30-day fair value range of $25.64 to $27.24.
Technical Outlook: Technically, MAZE is in a strong downtrend. The price is currently testing key support at $24.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $63.00 (+157.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MAZE is in a strong downtrend. The price is currently testing key support at $24.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $63.00 (+157.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$25.64 -
$27.24
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 157.1% below Wall St target ($63.00)
Trading Range Analysis
30-Day Trading Range
$25.64 -
$27.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$24.40
Resistance Level
$27.58
Current Trend
Strong Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.56
Wall Street Target
$63.00
(+157.1%)
Share & Embed Analysis
Last updated: May 18, 2026 5:18 PM ET
Data refreshes hourly during market hours. Next update: 6:18 PM
Data refreshes hourly during market hours. Next update: 6:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MAZE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Harold Bernstein
SELL
15000 shares
2026-04-01
Amy Bachrodt
SELL
2500 shares
2026-04-01
Harold Bernstein
SELL
15000 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 50 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
